Detailed Information on Publication Record
2020
Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy
MACHÁČKOVÁ, Táňa, Karolína TRACHTOVÁ, Vladimír PROCHÁZKA, Tomáš GROLICH, Martina FARKAŠOVÁ et. al.Basic information
Original name
Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy
Authors
MACHÁČKOVÁ, Táňa (203 Czech Republic, belonging to the institution), Karolína TRACHTOVÁ (203 Czech Republic, belonging to the institution), Vladimír PROCHÁZKA (203 Czech Republic, belonging to the institution), Tomáš GROLICH (203 Czech Republic, belonging to the institution), Martina FARKAŠOVÁ (703 Slovakia, belonging to the institution), Lukáš FIALA (203 Czech Republic), Roman ŠEFR (203 Czech Republic), Igor KISS (203 Czech Republic), Matej SKROVINA (203 Czech Republic), Michal DOSOUDIL (203 Czech Republic), Ioana BERINDAN-NEAGOE (642 Romania), Marek SVOBODA (203 Czech Republic), Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution) and Zdeněk KALA (203 Czech Republic, belonging to the institution)
Edition
CANCER GENOMICS & PROTEOMICS, ATHENS, INT INST ANTICANCER RESEARCH, 2020, 1109-6535
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Greece
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.069
RIV identification code
RIV/00216224:14740/20:00118648
Organization unit
Central European Institute of Technology
UT WoS
000530098500004
Keywords in English
Rectal cancer; chemoradiotherapy; microRNA; prediction
Tags
International impact, Reviewed
Změněno: 10/3/2021 16:15, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
Background/Aim: Rectal cancer accounts for approximately one-third of all colorectal cancers. Currently, the standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (CRT) with capecitabine or 5-fluorouracil followed by curative surgery. Unfortunately, only 20% of patients with LARC present complete pathological response after CRT, whereas in 20-40% cases the response is poor or absent. The aim of our study was to evaluate whether microRNAs (miRNAs) in tumor biopsy specimen have the potential to predict therapeutic response in LARC patients. Patients and Methods: In total 87 LARC patients treated by CRT were enrolled in our prospective study. To identify predictive miRNAs, we used small RNA sequencing in 40 tumor biopsy samples of LARC patients (20 responders, 20 non-responders) and qPCR validation of selected miRNA candidates. Results: In the discovery phase of the study, we identified 69 miRNAs to have significantly different expression between the group of responders (TRG 1,2) and a group of non-responders (TRG 4,5) to neoadjuvant CRT. Among these miRNAs, 48 showed a lower expression and 21 showed higher expression in tumor tissues from poorly responding LARC patients. Five miRNAs were selected for validation, but only miR-487a-3p was confirmed to have a significantly higher expression in the tumor biopsy specimens of non-responders to neoadjuvant CRT (p<0.0006, AUC=0.766). Gene Ontology (GO) clustering and pathway enrichment analysis of the miR-487a-3p mRNA targets, revealed potential mechanisms behind miR487a-3p roles in chemoradioresistance (e.g. TGF-beta signaling pathway, protein kinase activity, double-stranded DNA binding, or microRNAs in cancer). Conclusion: By combination of miRNA expression profiling and integrative computational biology we identified miR-487a-3p as a potential predictive biomarker of CRT response in LARC patients.
Links
NV16-31765A, research and development project |
|